AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1008239 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dextran)
Number of subjects: 0
Study 31029171 — intervention group
Group type: EXPERIMENTAL
Intervention: SAIA-SCALE intervention
Number of subjects: 36
Study 27726925 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3g·day‐1)
Number of subjects: 13
Study 28247675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitaprost forte (rectal suppositories) and Vitaprost tablets
Number of subjects: 90
Study 28247675 — intervention group
Group type: COMPARATOR
Intervention: Standard anti-inflammatory therapy
Number of subjects: 90
Study 28247675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitaprost treatment
Number of subjects: 90
Study 23188563 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Port (SP) Cholecystectomy
Number of subjects: 105
Study 23188563 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopic (ML) Cholecystectomy
Number of subjects: 105
Study 23188563 — intervention group
Group type: COMPARATOR
Intervention: Conventional Laparoscopic (CL) Cholecystectomy
Number of subjects: 105
Study 21881478 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg once daily
Number of subjects: 157
Study 21881478 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 157
Study 21881478 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine
Number of subjects: 157
Study 19367649 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent thermotesting device
Number of subjects: 0
Study 19367649 — intervention group
Group type: COMPARATOR
Intervention: Commercially available thermotesting device
Number of subjects: 0
Study 16769295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 16769295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 16769295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15761556 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH + R before breakfast and lunch and bedtime NPH (Group B)
Number of subjects: 53
Study 15761556 — intervention group
Group type: COMPARATOR
Intervention: NPH + R before dinner and bedtime NPH (Group A)
Number of subjects: 53
Study 11060833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib
Number of subjects: 0
Study 11060833 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac (Control)
Number of subjects: 0
Study 9116434 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 therapy (2 mmol/kg/day for 7 days)
Number of subjects: 53
Study 9116434 — intervention group
Group type: COMPARATOR
Intervention: NaCl therapy (2 mmol/kg/day for 7 days)
Number of subjects: 53
Study 7506150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 200mg
Number of subjects: 39
Study 7506150 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 500mg
Number of subjects: 39
Study 2411246 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimeldine (individualized doses to achieve plasma concentrations of 50 to 100 ng/mL)
Number of subjects: 4
Study 2411246 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimeldine
Number of subjects: 4
Study 2411246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 30236237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg kg-1
Number of subjects: 375
Study 30236237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 16 mg kg-1
Number of subjects: 375
Study 30236237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 26754331 — intervention group
Group type: EXPERIMENTAL
Intervention: AndroForte 5 testosterone cream
Number of subjects: 16
Study 26754331 — intervention group
Group type: COMPARATOR
Intervention: Testogel 1% testosterone gel
Number of subjects: 16
Study 24590635 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole-lapatinib
Number of subjects: 92
Study 24590635 — intervention group
Group type: COMPARATOR
Intervention: letrozole-placebo
Number of subjects: 92
Study 21339763 — intervention group
Group type: EXPERIMENTAL
Intervention: Compact catheter
Number of subjects: 30
Study 21339763 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 30
Study 16003272 — intervention group
Group type: EXPERIMENTAL
Intervention: Young African Americans (AAs)
Number of subjects: 122
Study 16003272 — intervention group
Group type: COMPARATOR
Intervention: Caucasians (Control)
Number of subjects: 122
Study 12468746 — intervention group
Group type: EXPERIMENTAL
Intervention: Sherbrooke model arm (combined occupational and clinical interventions)
Number of subjects: 0
Study 12468746 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational arm
Number of subjects: 0
Study 12468746 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical arm
Number of subjects: 0
Study 12468746 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 9796053 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV/Hib vaccines co-administered with oral polio vaccine
Number of subjects: 269
Study 7637191 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (0.03 mg.kg‐1)
Number of subjects: 30
Study 7637191 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.03 mg.kg‐1) after succinylcholine (1.0 mg.kg‐1)
Number of subjects: 30
Study 7637191 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1.0 mg.kg‐1) followed by vecuronium (0.03 mg.kg‐1)
Number of subjects: 30
Study 2793383 — intervention group
Group type: EXPERIMENTAL
Intervention: Acivicin (60 mg/m2/course, administered as a 72‐hr infusion)
Number of subjects: 66
Study 2793383 — intervention group
Group type: COMPARATOR
Intervention: Vinblastine (7.5 mg/m2/course, administered as a 120‐hr infusion)
Number of subjects: 66
Study 350473 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg aspirin and 64 mg caffeine (aspirin-caffeine)
Number of subjects: 140
Study 350473 — intervention group
Group type: COMPARATOR
Intervention: 650 mg aspirin
Number of subjects: 140
Study 350473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 30115103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ivabradine
Number of subjects: 19
Study 30115103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 27097690 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope Videolaryngoscope (GVL)
Number of subjects: 80
Study 27097690 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MCL)
Number of subjects: 80
Study 25794628 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogen clamp
Number of subjects: 274
Study 25794628 — intervention group
Group type: COMPARATOR
Intervention: Gomco clamp
Number of subjects: 274
Study 24102344 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus iloprost (administered for 10 days every 3 months)
Number of subjects: 101
Study 24102344 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (Control Group A)
Number of subjects: 101
Study 24102344 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus iloprost
Number of subjects: 101
Study 20498326 — intervention group
Group type: EXPERIMENTAL
Intervention: RDEA806 (400 mg twice a day)
Number of subjects: 48
Study 20498326 — intervention group
Group type: EXPERIMENTAL
Intervention: RDEA806 (600 mg once a day)
Number of subjects: 48
Study 20498326 — intervention group
Group type: EXPERIMENTAL
Intervention: RDEA806 (800 mg once a day)
Number of subjects: 48
Study 20498326 — intervention group
Group type: EXPERIMENTAL
Intervention: RDEA806 (1,000 mg once a day)
Number of subjects: 48
Study 20498326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 17852292 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong intervention
Number of subjects: 57
Study 17852292 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 57
Study 17852292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (intervention + control after crossover)
Number of subjects: 57
Study 16552549 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon with metal interference screw fixation
Number of subjects: 99
Study 16552549 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon with titanium metal plate suspension and screw-washer postdistally
Number of subjects: 99
Study 16552549 — intervention group
Group type: COMPARATOR
Intervention: Hamstring tendon group
Number of subjects: 99
Study 16552549 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 99
Study 14634404 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal sensation test used during apical biopsy
Number of subjects: 30
Study 14634404 — intervention group
Group type: COMPARATOR
Intervention: Control group without rectal sensation test
Number of subjects: 30
Study 10801252 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanepitant (20, 60, 200, or 600 mg initial dose, followed by 10, 30, 100, or 300 mg twice a day)
Number of subjects: 214
Study 10801252 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (375 mg twice a day)
Number of subjects: 214
Study 10801252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 8835282 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (equivalent to a single cup of strong coffee)
Number of subjects: 2
Study 8835282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 1333910 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMOS alone
Number of subjects: 135
Study 1333910 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMOS plus CDDP
Number of subjects: 135
Study 1333910 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 135
Study 6692582 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) after hypophysectomy
Number of subjects: 9
Study 6692582 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) after adrenalectomy
Number of subjects: 9
Study 6692582 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG)
Number of subjects: 9
Study 30810332 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD patients (120 patients)
Number of subjects: 403
Study 30024798 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month intervention including food, diabetes education, health care referral, and glucose monitoring
Number of subjects: 568
Study 30024798 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 568
Study 26930341 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone Suture Plate (SSP) device
Number of subjects: 8
Study 26930341 — intervention group
Group type: COMPARATOR
Intervention: Standard suturing techniques
Number of subjects: 8
Study 24650002 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP monitoring
Number of subjects: 90
Study 24650002 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 22697441 — intervention group
Group type: EXPERIMENTAL
Intervention: False safety behavior elimination therapy (F-SET)
Number of subjects: 96
Study 22697441 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 96
Study 20102889 — intervention group
Group type: EXPERIMENTAL
Intervention: Grayscale IVUS attenuated plaques
Number of subjects: 64
Study 20102889 — intervention group
Group type: EXPERIMENTAL
Intervention: VH-TCFA (thin-capped fibroatheromas)
Number of subjects: 64
Study 20102889 — intervention group
Group type: EXPERIMENTAL
Intervention: VH-ThFA (thick-capped fibroatheromas)
Number of subjects: 64
Study 20102889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic intimal thickening
Number of subjects: 64
Study 20102889 — intervention group
Group type: COMPARATOR
Intervention: Control sites (remaining 65 vessels)
Number of subjects: 64
Study 18568502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal microemulsion treatment
Number of subjects: 0
Study 18568502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15821951 — intervention group
Group type: EXPERIMENTAL
Intervention: LY544344 (80 mg bid for 1 week)
Number of subjects: 12
Study 15821951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11830461 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet (60 mg/kg for 2 weeks, then 90 mg/kg for 2 weeks if needed)
Number of subjects: 213
Study 11830461 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir (5 mg/kg every 12 hours for 2 weeks, then 6 mg/kg once daily for 5 days per week if needed)
Number of subjects: 213
Study 11830461 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet and Ganciclovir
Number of subjects: 213
Study 12212053 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (along with antibiotics and oxygen) for 14 days
Number of subjects: 36
Study 12212053 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics and oxygen
Number of subjects: 36
Study 7542965 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser prostatectomy using Prolase-II fiber at 40 W for 90 s
Number of subjects: 30
Study 7542965 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 2202461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine, 1 mg/kg daily from days 1-28 administered intravenously in four patients and orally in five.
Number of subjects: 9
Study 2202461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 9
Study 6988169 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 104
Study 6988169 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cephradine administered twice daily for 1 week
Number of subjects: 104
Study 6988169 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cephradine administered 4-times a day
Number of subjects: 104
Study 6988169 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 104
Study 31511629 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG-B intervention (12 sessions)
Number of subjects: 40
Study 31511629 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (12 weeks, 24 sessions)
Number of subjects: 40
Study 28502596 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum (CCH)
Number of subjects: 1493
Study 25819531 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Glargine (IG)
Number of subjects: 66
Study 25819531 — intervention group
Group type: COMPARATOR
Intervention: Neutral Protamine Hagedorn (NPH) insulin
Number of subjects: 66
Study 23706362 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss treatment
Number of subjects: 113
Study 21362084 — intervention group
Group type: EXPERIMENTAL
Intervention: SNaP(®) Wound Care System
Number of subjects: 65
Study 21362084 — intervention group
Group type: COMPARATOR
Intervention: VAC(®) Therapy System
Number of subjects: 65
Study 18955102 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (220 mg/day)
Number of subjects: 119
Study 18955102 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA+AA (220 mg/day each)
Number of subjects: 119
Study 18955102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 17484791 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 0
Study 17484791 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 0
Study 15028313 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 gastrectomy
Number of subjects: 162
Study 15028313 — intervention group
Group type: COMPARATOR
Intervention: D2 gastrectomy
Number of subjects: 162
Study 15028313 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 162
Study 11213243 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhiatal esophagectomy
Number of subjects: 10
Study 11213243 — intervention group
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic assessment of swallowing
Number of subjects: 10
Study 10050456 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral pulse therapy with methylprednisolone, 1000 mg daily for three days
Number of subjects: 28
Study 10050456 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pulse therapy with methylprednisolone, 1000 mg daily for three days
Number of subjects: 28
Study 10050456 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral pulse therapy with methylprednisolone
Number of subjects: 28
Study 8065284 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg tablet, twice daily
Number of subjects: 40
Study 8065284 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen mouthwash 10 ml (0.25%), rinsed 6 times daily for three minutes
Number of subjects: 40
Study 3385024 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minoxidil gel
Number of subjects: 64
Study 3385024 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minoxidil solution
Number of subjects: 64
Study 3385024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 29450903 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical education (PE) from 60 to 200 minutes per week
Number of subjects: 304
Study 29450903 — intervention group
Group type: COMPARATOR
Intervention: Standard physical education (PE) of 60 minutes per week
Number of subjects: 304
Study 26768926 — intervention group
Group type: EXPERIMENTAL
Intervention: Proseal laryngeal mask airway insertion
Number of subjects: 100
Study 26768926 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 100
Study 25470803 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3mg*kg‐1)
Number of subjects: 19
Study 25470803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 22993340 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane therapy for 30 months
Number of subjects: 0
Study 22993340 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen followed by exemestane
Number of subjects: 0
Study 22993340 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics use
Number of subjects: 0
Study 19818953 — intervention group
Group type: EXPERIMENTAL
Intervention: W‐CBT (cognitive‐behavioural worry intervention)
Number of subjects: 24
Study 19818953 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 24
Study 17715042 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin tablet (500 mg) from pharmaceutical company 1
Number of subjects: 18
Study 17715042 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin tablet (500 mg) from pharmaceutical company 2
Number of subjects: 18
Study 17715042 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin tablet (500 mg) from pharmaceutical company 3
Number of subjects: 18
Study 16246409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide (n=6)
Number of subjects: 11
Study 16246409 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (n=5)
Number of subjects: 11
Study 16246409 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 11
Study 10940175 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (3-day course)
Number of subjects: 42
Study 10940175 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate (2-week course)
Number of subjects: 42
Study 9265992 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch testing
Number of subjects: 113
Study 9265992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk challenge
Number of subjects: 113
Study 9265992 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test
Number of subjects: 113
Study 9265992 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch test
Number of subjects: 113
Study 9265992 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysensitization
Number of subjects: 113
Study 8334031 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 400 mg daily for 30 days, followed by 60 days of no treatment (Group 2)
Number of subjects: 60
Study 8334031 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol 2 mcg for 5 days and clodronate 400 mg daily for additional 25 days, followed by 60 days of no treatment (Group 3)
Number of subjects: 60
Study 8334031 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group 1)
Number of subjects: 60
Study 8334031 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (Group 2)
Number of subjects: 60
Study 3568691 — intervention group
Group type: EXPERIMENTAL
Intervention: Biostatistical Monitoring Committee
Number of subjects: 0
Study 3348152 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 kcal/min Realmentyl
Number of subjects: 10
Study 3348152 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3 kcal/min Realmentyl
Number of subjects: 10
Study 3348152 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 10
Study 31352663 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical compounds (red yeast rice, Berberine, Coenzyme Q10, folic acid and chrome) added to diet for 3 months
Number of subjects: 131
Study 31352663 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 131
Study 28790226 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (3 x 500 mg)
Number of subjects: 120
Study 28790226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25999334 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference-focused psychotherapy (TFP)
Number of subjects: 104
Study 25999334 — intervention group
Group type: COMPARATOR
Intervention: Treatment by experienced community therapists
Number of subjects: 104
Study 24261946 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a grass pollen tablet for 4 months
Number of subjects: 82
Study 24261946 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 82
Study 22150686 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduction filtration performed at designated intervals post-collection after storage in transport shippers for at least 2 hours.
Number of subjects: 50
Study 22150686 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage times ranged from 28 to 458 minutes before leukoreduction filtration.
Number of subjects: 50